Nestlé invests $145M in food allergy company

Nestlé Health Science's investment could speed development of Aimmune's immunotherapy for peanut allergy.

By Suzanne Elvidge • Nov. 7, 2016

Prescribed Reading: ASH abstracts hit biotech hard

Companies refocus their M&A strategies, while abstracts from the upcoming ASH meeting disappoint investors and new discoveries could help treat a rare disease. 

By Lisa LaMotta • Nov. 4, 2016

EnBiotix gets the bug for AMPT antimicrobials

The bioengineering company has acquired German AMP Therapeutics and its portfolio of anti-microbial peptides. 

By Suzanne Elvidge • Nov. 4, 2016

Troubled Infinity licenses cancer drug to Verastem

The Cambridge-based biotech is attempting to adjust after a terminated partnership with AbbVie and lackluster trial results buried the company's stock. 

By Jacob Bell • Nov. 3, 2016

Ergomed, Asarina partner on treatment for severe premenstrual syndrome

Sepranolone is the first product being developed exclusively for the often-debilitating condition.

By Judy Packer-Tursman • Nov. 3, 2016

Mitsubishi strengthens arthritis portfolio with TissueGene deal

The licensing partnership comes as a growing share of Japan's population is dealing with joint problems.

By Jacob Bell • Nov. 2, 2016

Allergan: More M&A, international expansion

The specialty pharma told analysts during its third quarter call it will continue to focus on deals to flesh out its pipeline. 

By Jacob Bell • Nov. 2, 2016

What would a Salix sale do for Valeant?

The embattled drugmaker confirmed a report from The Wall Street Journal, indicating the Salix portfolio and its top-selling gut drug Xifaxan are on the table. 

By Ned Pagliarulo • Nov. 2, 2016

Astellas furthers oncology focus with Ganymed buy

The deal, which could have Astellas paying upwards of $1.4 billion, gives the company a stronger presence in oncology outside of the blockbuster drug Xtandi.

By Jacob Bell • Oct. 28, 2016

Prescribed Reading: Dealmaking sparse, despite earnings reports

Analysts question Allergan's latest buy, Bristol-Myers shuffles R&D and FDA makes some proclamations about sex. 

By Lisa LaMotta • Oct. 28, 2016

Evotec picks up CRO Cyprotex for $68M

The German drug discovery company has been active in M&A, inking a number of deals over the past several years. 

By Jacob Bell • Oct. 27, 2016

Continuing M&A spree, Allergan picks up Motus for $200M

Allergan has been aggressive in expanding its pipeline, inking a series of stepping-stone deals over the past several months. 

By Ned Pagliarulo • Oct. 27, 2016

Bayer aims to cut costs ahead of Monsanto deal

The German biopharma is trimming its spending as it preps to spend more than $66 billion on Monsanto. 

By Jacob Bell • Oct. 26, 2016

NeuroVive claws back rights to hep B drug

Partner Arbutus Biopharma had halted development of the experimental drug a year ago, but the companies were unable to agree on a path forward until now. 

By Suzanne Elvidge • Oct. 24, 2016

Prescribed Reading: Only one FDA approval in October so far

While few deals flowed in this week, there was plenty of clinical data dominating pharma news.

By Lisa LaMotta • Oct. 21, 2016

AbbVie dumps Ablynx RA drug

Ablynx will have to go it alone in Phase 3 while it looks for a new partner for vobarilizumab. 

By Lisa LaMotta • Oct. 20, 2016

Novartis links up with Cerulean in NDC deal

The Swiss pharma is adding the linker technology to its oncology pipeline as it focuses on combination therapies. 

By Lisa LaMotta • Oct. 19, 2016

Moderna taps Catalent for clinical manufacturing

The well-funded Cambridge biotech has been busy expanding its manufacturing capacity as it ramps up clinical development of several mRNA programs. 

By Jacob Bell • Oct. 17, 2016

PwC: Biotech deal values and volume drop

PwC's latest MoneyTree report depicts a biotech sector struggling to maintain the record levels of investment activity seen last year.

By Suzanne Elvidge • Oct. 17, 2016

Prescribed Reading: AZ sell-off, Merck wins ESMO, generics dominate

Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week.

By Lisa LaMotta • Oct. 13, 2016

Intellipharmaceutics and Mallinckrodt ink CNS deal

The companies have signed an agreement to market three central nervous system generics for $3 million in hopes of quick FDA approvals. 

By Joe Cantlupe • Oct. 13, 2016

Regeneron eyes long-lasting Eylea in deal with Ocular

The companies said the new drug would benefit consumers by enabling lower dosing and fewer trips to the doctor.

By Jacob Bell • Oct. 13, 2016

AstraZeneca snaps up Amgen site in Colorado

The newly acquired facility will support another Colorado plant AstraZeneca bought from Amgen last year, both of which are focused on biologics. 

By Suzanne Elvidge • Oct. 13, 2016

Verily, 3M team up to measure healthcare costs

Formerly Google Life Sciences, Verily has also recently launched partnerships with a range of big pharmas, including Sanofi and GSK. 

By Joe Cantlupe • Oct. 12, 2016

Merck KGaA, Pfizer and Transgene team up on cancer vaccine

The French biotech announced collaborations with Merck KGaA and Pfizer to evaluate its HPV-positive head and neck cancer vaccine in combo with avelumab.

By Joe Cantlupe • Oct. 12, 2016